Chronic Lymphocytic Leukemia
Chronic Lymphocytic Leukemia
The latest news, research, and perspectives in chronic lymphocytic leukemia (CLL). The most common leukemia subtype among adults, CLL occurs when an acquired mutation causes bone marrow to produce abnormal lymphocytes. As these leukemic cells proliferate, the disorder is associated with lymphadenopathy, splenomegaly, and cytopenias.
Advertisement
Cecilia BrownChronic Lymphocytic Leukemia | February 28, 2023
Novel multiclonal second site BTK mutations can lead to resistance in patients with pre-existing BTK C481 mutations.
Read More
Cecilia BrownChronic Lymphocytic Leukemia | February 28, 2023
A new mutational signature was present in the Richter’s transformation sample from seven of 18 patients.
Cecilia BrownChronic Lymphocytic Leukemia | February 28, 2023
The multi-omics study identified six CLL subgroups, five of which were associated with genetic features.
Cecilia BrownChronic Lymphocytic Leukemia | February 28, 2023
The median OS was four months from the date of Richter's transformation, suggesting prognosis "remains poor."
Leah SherwoodChronic Lymphocytic Leukemia | January 19, 2023
The U.S. Food and Drug Administration (FDA) has approved zanubrutinib for the treatment of CLL and SLL.
Leah SherwoodChronic Lymphocytic Leukemia | January 13, 2023
BCL2 inhibitors (eg, venetoclax) have clinical benefits for patients with CLL, but overcoming resistance remains a challenge.
Advertisement
Cecilia BrownChronic Lymphocytic Leukemia | January 13, 2023
Moxetumomab pasudotox will be discontinued from the market in the US in July 2023.
Leah SherwoodPrint | January 13, 2023
The European Commission has approved zanubrutinib for the treatment of adults with chronic lymphocytic leukemia.
Chadi Nabhan, MD, MBA, FACPThe HemOnc Pulse | January 12, 2023
In this episode, Chadi Nabhan, MD, MBA, FACP, talks with Elizabeth Brem, MD, about CLL highlights from ASH 2022.
Matthew Davids, MD, MMScVideo Insights | January 9, 2023
Matthew Davids, MD, MMSc, of the Dana-Farber Cancer Institute, shares his hopes for CLL treatment and research in 2023.
Leah SherwoodMeeting News | December 20, 2022
In follow-up data from the phase II CAPTIVATE study, ibrutinib plus venetoclax demonstrated a favorable benefit-risk profile.
Cecilia BrownMeeting News | December 20, 2022
Zanubrutinib may be “more efficacious and better tolerated” than ibrutinib for patients with relapsed/refractory CLL or ...
Jennifer R. Brown, MD, PhDVideo Insights | December 20, 2022
SOHO President Jennifer R. Brown, MD, PhD, speaks about the phase III ALPINE study, which compared BTK inhibitors in CLL/SLL.
Leah SherwoodChronic Lymphocytic Leukemia | December 20, 2022
The CLL2-Give trial determined that obinutuzumab, ibrutinib, and venetoclax is a “potent and promising” treatment for ...
Cecilia BrownChronic Lymphocytic Leukemia | December 20, 2022
Patients with chronic lymphocytic leukemia (CLL) primarily rely on their physicians for information about their disease.
Chadi Nabhan, MD, MBA, FACPChronic Lymphocytic Leukemia | December 13, 2022
Jennifer R. Brown, MD, PhD; President of SOHO chats with Chadi Nabhan, MD, on the ALPINE study.
Cecilia BrownMeeting News | December 11, 2022
Christine Ryan, MD, discusses research presented at the 2022 American Society of Hematology Annual Meeting.
Leah SherwoodMyeloma | December 1, 2022
At Blood Cancers Today, we have compiled the year's top content awards as doled out by the Twitterverse. 
Cecilia BrownChronic Lymphocytic Leukemia | October 24, 2022
A new assay for the quantification of MRD in CLL can detect MRD to 10-5 and below.
Cecilia BrownChronic Lymphocytic Leukemia | October 24, 2022
A new study suggests small extracellular vesicles secreted by leukemia cells reduce anti-tumor T-cell responses.
Advertisement
Advertisement
Editorial Board